Research on, and interest in, red blood cell formation spans several centuries and was thought to have peaked in the 1980s with the cloning of the eryth- poietin (EPO) gene. In the years subsequent to the cloning of EPO and its expression as a recombinant protein, much was written about EPO. Although much has been learned and published, new, exciting data are becoming ava- able on almost a daily basis. Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology compiles both pertinent historical and very recent research on this molecule and its clinical utility....
Research on, and interest in, red blood cell formation spans several centuries and was thought to have peaked in the 1980s with the cloning of the ery...
This monograph contains a description of the discovery and development of a new antisecretory therapy in the treatment of acid-related disea ses: omeprazole, the first proton pump inhibitor. The pharmacology of different proton pump inhibitors, the pharmaceutic delivery system and the clinical experience with proton pump inhibitors is reviewed. The book is aimed at a broad readership with an interest in the developme nt problems of this, at present, most commercially successful drug; th e pharmacology of a ttailor-madev drug for a specific target; the ther apeutic strategies in acid-related...
This monograph contains a description of the discovery and development of a new antisecretory therapy in the treatment of acid-related disea ses: omep...
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent...
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ...
In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields to review the state of the art advances on topics ranging from disease entities to vectors and engineered cells. The different approaches described in each chapter take into consideration the biomedical knowledge of these diseases and address the complexities of delivering long-term genetic interventions. Gene therapy also serves as a testing ground for new therapeutic entities and helps provide proof of principle for their potential...
In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields...
Multiple Myeloma (MM) is the second most-common blood cancer. Bortezomib is a promising anticancer-drug targeting the proteasome. This monograph on bortezomib is a valuable source of information for researchers and clinicians from oncology and pharmacology.
Multiple Myeloma (MM) is the second most-common blood cancer. Bortezomib is a promising anticancer-drug targeting the proteasome. This monograph on bo...
Both metabotropic and ionotropic glutamate receptors present attractive "druggable" targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This "Milestones in Drug Therapy" volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and...
Both metabotropic and ionotropic glutamate receptors present attractive "druggable" targets in treating disorders of the central nervous system. There...
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled 2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical...
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with a...
Malaria has defeated previous efforts at eradication and remains a massive global public health problem despite being readily preventable and treatable. It is a devastating disease that also extracts huge economic costs from the poorest countries in endemic regions.
Starting with an overview of the disease and its current political, financial and technical context, this Milestones in Drug Therapy volume describes the history, chemistry, mechanisms of action and resistance, preclinical and clinical use, pharmacokinetics and safety and tolerability of the current range of...
Malaria has defeated previous efforts at eradication and remains a massive global public health problem despite being readily preventable and treat...
This book provides a detailed overview of B-cell directed therapies in patients with rheumatic and systemic autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, Sjogren syndrome, ANCA-associated vasculitis and cryoglobulinemia. Organ-specific autoimmune diseases are discussed with respect to the use of B-cell directed therapies in neurological autoimmune diseases and autoimmune cytopenias. Situations in which B-cell targeted therapy may be indicated are identified, thereby offering comprehensive support for therapeutic decisions on the basis of the latest...
This book provides a detailed overview of B-cell directed therapies in patients with rheumatic and systemic autoimmune diseases, including rheumato...
In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields to review the state of the art advances on topics ranging from disease entities to vectors and engineered cells. The different approaches described in each chapter take into consideration the biomedical knowledge of these diseases and address the complexities of delivering long-term genetic interventions. Gene therapy also serves as a testing ground for new therapeutic entities and helps provide proof of principle for their potential...
In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields...
